-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] As the first quarter of 2022 is gradually coming to an end, many pharmaceutical companies have recently begun to release performance forecasts for the first quarter of 2022
.
For example, Xin Litai, Jiangzhong Pharmaceutical, Kelun Pharmaceutical, and Proton have all recently released the company's first-quarter performance forecast
.
Among them, Xin Litai stated in the first quarter performance forecast of 2022 that the net profit attributable to shareholders of listed companies during the reporting period increased by 36.
45%-69.
44% year-on-year, about 211.
5767 million yuan-262.
7271 million yuan
.
Jiangzhong Pharmaceutical expects that in the first quarter of 2022, its net profit attributable to shareholders of listed companies will increase by 15% year-on-year to about 183 million yuan; it is expected to increase its non-net profit by about 20% year-on-year to about 172 million yuan
.
Kelun Pharmaceutical expects that in the first quarter of 2022, the year-on-year growth rate of net profit attributable to the parent will rebound to 32%, 50%-70%, and the generic drug business will usher in a cash-out period
.
And Proton shares is expected to achieve a year-on-year increase of 150%-170% in operating income in the first quarter of 2022, about 1.
357 billion yuan to 1.
466 billion yuan; it is expected to achieve a year-on-year increase of 270%-290% in net profit attributable to shareholders of listed companies, about It is 326 million yuan – 344 million yuan
.
As for the company's performance growth, Xin Litai's announcement showed that it was mainly due to the overall increase in sales revenue
.
Among them, Xinlitan, an innovative drug, has undergone a new round of negotiation to renew the National Medical Insurance Catalogue.
In the first quarter, when the price dropped by nearly 30% year-on-year, the sales volume increased rapidly, and the sales were basically flat year-on-year; in addition, in 2021 The sales revenue of generic drugs that won the bid for national centralized procurement in the year achieved a good growth
.
Jiangzhong Pharmaceutical said that in the first quarter of 2022, the company will focus on the three major business priorities of "focusing on OTC, developing general health, and strengthening prescription drugs", strengthening brand building, expanding market layout, and maintaining a good momentum in product sales.
At the same time, the newly acquired company Jincheng According to the consolidated data of Hays Pharmaceutical Co.
, Ltd.
, the company's operating performance has achieved good growth
.
Proton shares said that benefiting from the continued high prosperity of the CDMO industry, the company's customer pipeline and product pipeline continued to expand and enrich, the company's orders in hand in the first quarter of 2021 grew strongly, and the major orders received in the early stage were delivered smoothly one after another.
At the same time, through continuous improvement of R&D technical capabilities and delivery capabilities, the company's profitability has been further improved, and the profit growth has exceeded the revenue growth
.
It is understood that Proton shares stand out in the innovative drug research and development track.
From the perspective of performance, not only its revenue and net profit have both surged in the first quarter of 2022, but its performance in the past three years has also been quite dazzling
.
For example, in 2021, the company's operating income and net profit will increase by 50% and 61% year-on-year, respectively, to 3.
105 billion yuan and 524 million yuan
.
It is reported that in recent years, Proton has continued to expand its team strength.
In 2021, the number of Proton employees will increase by 44% year-on-year to 3,782, and the R&D technical team will increase by 68% year-on-year, exceeding 1,200
.
Analysts pointed out that the performance of pharmaceutical industry companies in the first quarter of 2022 is expected to exceed expectations
.
As the agency expects, as the country increases nucleic acid screening and the approval of antigen detection reagents, the net profit margins of beneficiary companies such as Wanfu Bio, Mingde Bio, Kaipu Bio, and Yahuilong are expected to exceed 100% and grow rapidly
.
In addition, some people said that after the previous adjustment, the investment value of the pharmaceutical sector has become prominent, and it is currently in the period of annual report and quarterly report performance disclosure.
Companies with high growth or exceeding expectations may be favored by the market
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
For example, Xin Litai, Jiangzhong Pharmaceutical, Kelun Pharmaceutical, and Proton have all recently released the company's first-quarter performance forecast
.
Among them, Xin Litai stated in the first quarter performance forecast of 2022 that the net profit attributable to shareholders of listed companies during the reporting period increased by 36.
45%-69.
44% year-on-year, about 211.
5767 million yuan-262.
7271 million yuan
.
Jiangzhong Pharmaceutical expects that in the first quarter of 2022, its net profit attributable to shareholders of listed companies will increase by 15% year-on-year to about 183 million yuan; it is expected to increase its non-net profit by about 20% year-on-year to about 172 million yuan
.
Kelun Pharmaceutical expects that in the first quarter of 2022, the year-on-year growth rate of net profit attributable to the parent will rebound to 32%, 50%-70%, and the generic drug business will usher in a cash-out period
.
And Proton shares is expected to achieve a year-on-year increase of 150%-170% in operating income in the first quarter of 2022, about 1.
357 billion yuan to 1.
466 billion yuan; it is expected to achieve a year-on-year increase of 270%-290% in net profit attributable to shareholders of listed companies, about It is 326 million yuan – 344 million yuan
.
As for the company's performance growth, Xin Litai's announcement showed that it was mainly due to the overall increase in sales revenue
.
Among them, Xinlitan, an innovative drug, has undergone a new round of negotiation to renew the National Medical Insurance Catalogue.
In the first quarter, when the price dropped by nearly 30% year-on-year, the sales volume increased rapidly, and the sales were basically flat year-on-year; in addition, in 2021 The sales revenue of generic drugs that won the bid for national centralized procurement in the year achieved a good growth
.
Jiangzhong Pharmaceutical said that in the first quarter of 2022, the company will focus on the three major business priorities of "focusing on OTC, developing general health, and strengthening prescription drugs", strengthening brand building, expanding market layout, and maintaining a good momentum in product sales.
At the same time, the newly acquired company Jincheng According to the consolidated data of Hays Pharmaceutical Co.
, Ltd.
, the company's operating performance has achieved good growth
.
Proton shares said that benefiting from the continued high prosperity of the CDMO industry, the company's customer pipeline and product pipeline continued to expand and enrich, the company's orders in hand in the first quarter of 2021 grew strongly, and the major orders received in the early stage were delivered smoothly one after another.
At the same time, through continuous improvement of R&D technical capabilities and delivery capabilities, the company's profitability has been further improved, and the profit growth has exceeded the revenue growth
.
It is understood that Proton shares stand out in the innovative drug research and development track.
From the perspective of performance, not only its revenue and net profit have both surged in the first quarter of 2022, but its performance in the past three years has also been quite dazzling
.
For example, in 2021, the company's operating income and net profit will increase by 50% and 61% year-on-year, respectively, to 3.
105 billion yuan and 524 million yuan
.
It is reported that in recent years, Proton has continued to expand its team strength.
In 2021, the number of Proton employees will increase by 44% year-on-year to 3,782, and the R&D technical team will increase by 68% year-on-year, exceeding 1,200
.
Analysts pointed out that the performance of pharmaceutical industry companies in the first quarter of 2022 is expected to exceed expectations
.
As the agency expects, as the country increases nucleic acid screening and the approval of antigen detection reagents, the net profit margins of beneficiary companies such as Wanfu Bio, Mingde Bio, Kaipu Bio, and Yahuilong are expected to exceed 100% and grow rapidly
.
In addition, some people said that after the previous adjustment, the investment value of the pharmaceutical sector has become prominent, and it is currently in the period of annual report and quarterly report performance disclosure.
Companies with high growth or exceeding expectations may be favored by the market
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
